 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Medivation, Inc.
MDVN
conference date: August 9, 2016 @ 1:30 PM Pacific Time
Medivation to be bought to Pfizer at $81.50 [August 22, 2016]
Medivation Rejects Sanofi Offer [April 29, 2016]
Medivation Looks Strong for 2015-2016 [04/09/2015 at Seeking Alpha]
2016 |
|||
05/05/2016 |
08/09/2016 |
||
2015 |
|||
05/07/2015 |
08/06/2015 |
11/05/2015 |
02/25/2016 |
Medivation is a manufacturer of a prostate cancer therapy.
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALNY |
| ALXN |
| AMAT |
| AMD |
| AMGN |
| BIIB |
| BIND |
| CLDX |
| CELG |
| EPZM |
| GILD |
| GLYC |
| HNSN |
| INO |
| INTC |
| ISRG |
| JUNO |
| MACK |
| MCHP |
| MDVN |
| MYL. |
| NVDA |
| OPXA |
| PLX |
| REGN |
| SGEN |
| XLNX |
| XLRN |
Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is investment journalism, not financial advice.
Copyright 2015 William P. Meyers